{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:19Z","timestamp":1787017099477,"version":"build-2736575974"},"reference-count":42,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing\u2013remitting multiple sclerosis switching from fingolimod.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from MSBase registry, this multicentre cohort study included subjects who had used fingolimod for \u22656 months and then switched to ocrelizumab, cladribine or natalizumab within 3 months after fingolimod discontinuation. We analysed relapse and disability outcomes after balancing covariates using an inverse-probability-treatment-weighting method. Propensity scores for the three treatments were obtained using multinomial-logistic regression. Due to the smaller number of cladribine users, comparisons of disability outcomes were limited to natalizumab and ocrelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1045 patients switched to ocrelizumab (n=445), cladribine (n=76) or natalizumab (n=524) after fingolimod. The annualised relapse rate (ARR) for ocrelizumab was 0.07, natalizumab 0.11 and cladribine 0.25. Compared with natalizumab, the ARR ratio (95% confidence interval [CI]) was 0.67 (0.47 to 0.96) for ocrelizumab and 2.31 (1.30 to 4.10) for cladribine; the hazard ratio (95%\u2009CI) for time to first relapse was 0.57 (0.40 to 0.83) for ocrelizumab and 1.18 (0.47 to 2.93) for cladribine. Ocrelizumab users had an 89% lower discontinuation rate (95%\u2009CI, 0.07 to 0.20) than natalizumab, but also a 51% lower probability of confirmed disability improvement (95%\u2009CI, 0.32 to 0.73). There was no difference in disability accumulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>After fingolimod cessation, ocrelizumab and natalizumab were more effective in reducing relapses than cladribine. Due to the low ARRs in all three treatment groups, additional observation time is required to determine if statistical difference in ARRs results in long-term disability differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2022-330104","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T13:25:23Z","timestamp":1666185923000},"page":"jnnp-2022-330104","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-7501","authenticated-orcid":false,"given":"Chao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0371-3666","authenticated-orcid":false,"given":"Izanne","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-1376","authenticated-orcid":false,"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas,","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavit","family":"Boz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-8864","authenticated-orcid":false,"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Horakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kubala Havrdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Macdonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3198-6063","authenticated-orcid":false,"given":"Samia Joseph","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-2495","authenticated-orcid":false,"given":"Marco","family":"Onofrj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Van Pesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Prevost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-4340","authenticated-orcid":false,"given":"Vilija","family":"Jokubaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"2022101910251048000_jnnp-2022-330104v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"2022101910251048000_jnnp-2022-330104v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70099-0"},{"key":"2022101910251048000_jnnp-2022-330104v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70056-X"},{"key":"2022101910251048000_jnnp-2022-330104v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"2022101910251048000_jnnp-2022-330104v1.5","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000096"},{"key":"2022101910251048000_jnnp-2022-330104v1.6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","article-title":"Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review","volume":"16","author":"Merkel","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2022101910251048000_jnnp-2022-330104v1.7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger","year":"2015","journal-title":"J Neuroimmunol"},{"key":"2022101910251048000_jnnp-2022-330104v1.8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol"},{"key":"2022101910251048000_jnnp-2022-330104v1.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.23732"},{"key":"2022101910251048000_jnnp-2022-330104v1.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.361"},{"key":"2022101910251048000_jnnp-2022-330104v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2022101910251048000_jnnp-2022-330104v1.12","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000360"},{"key":"2022101910251048000_jnnp-2022-330104v1.13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2022101910251048000_jnnp-2022-330104v1.14","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the clarity study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"key":"2022101910251048000_jnnp-2022-330104v1.15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","article-title":"Potential mechanisms of action related to the efficacy and safety of cladribine","volume":"30","author":"Baker","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2022101910251048000_jnnp-2022-330104v1.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"2022101910251048000_jnnp-2022-330104v1.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020696"},{"key":"2022101910251048000_jnnp-2022-330104v1.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2022101910251048000_jnnp-2022-330104v1.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"2022101910251048000_jnnp-2022-330104v1.20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40120-019-0129-0","article-title":"An overview of high-efficacy drugs for multiple sclerosis: Gulf region expert opinion","volume":"8","author":"Alroughani","year":"2019","journal-title":"Neurol Ther"},{"key":"2022101910251048000_jnnp-2022-330104v1.21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1080\/03007995.2019.1585779","article-title":"Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches","volume":"35","author":"Berardi","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2022101910251048000_jnnp-2022-330104v1.22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2022101910251048000_jnnp-2022-330104v1.23","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506070775"},{"key":"2022101910251048000_jnnp-2022-330104v1.24","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20703"},{"key":"2022101910251048000_jnnp-2022-330104v1.25","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"2022101910251048000_jnnp-2022-330104v1.26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/1352458516662728","article-title":"Data quality evaluation for observational multiple sclerosis registries","volume":"23","author":"Kalincik","year":"2017","journal-title":"Mult Scler"},{"key":"2022101910251048000_jnnp-2022-330104v1.27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"2022101910251048000_jnnp-2022-330104v1.28","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/87.3.706"},{"key":"2022101910251048000_jnnp-2022-330104v1.29","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"2022101910251048000_jnnp-2022-330104v1.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018174"},{"key":"2022101910251048000_jnnp-2022-330104v1.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"2022101910251048000_jnnp-2022-330104v1.32","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"2022101910251048000_jnnp-2022-330104v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"2022101910251048000_jnnp-2022-330104v1.34","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/67.1.145"},{"key":"2022101910251048000_jnnp-2022-330104v1.35","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq439"},{"key":"2022101910251048000_jnnp-2022-330104v1.36","doi-asserted-by":"crossref","unstructured":"Rubin DB . Multiple imputation for survey nonresponse. New York: Wiley, 1987.","DOI":"10.1002\/9780470316696"},{"key":"2022101910251048000_jnnp-2022-330104v1.37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"key":"2022101910251048000_jnnp-2022-330104v1.38","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/ene.13936","article-title":"Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis","volume":"26","author":"Boremalm","year":"2019","journal-title":"Eur J Neurol"},{"key":"2022101910251048000_jnnp-2022-330104v1.39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s13311-022-01202-1","article-title":"Comparative effectiveness of natalizumab versus anti-CD20 in highly active relapsing-remitting multiple sclerosis after fingolimod withdrawal","volume":"19","author":"Rollot","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2022101910251048000_jnnp-2022-330104v1.40","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1177\/1352458517728812","article-title":"Cladribine versus fingolimod, natalizumab and interferon \u03b2 for multiple sclerosis","volume":"24","author":"Kalincik","year":"2018","journal-title":"Mult Scler"},{"key":"2022101910251048000_jnnp-2022-330104v1.41","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000878","article-title":"Cladribine vs other drugs in MS: merging randomized trial with real-life data","volume":"7","author":"Signori","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2022101910251048000_jnnp-2022-330104v1.42","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-330104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T13:25:39Z","timestamp":1666185939000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-330104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":42,"alternative-id":["10.1136\/jnnp-2022-330104"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-330104","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}